Psoriasis Drug's skin gene secrets revealed in small trial
NCT ID NCT01872546
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the drug adalimumab affects gene activity in the skin of people with chronic plaque psoriasis. Researchers compared skin samples from normal, non-lesional, and lesional areas before and after treatment. The goal was to understand the immune changes that happen when the drug works, not to test if it works. Only 18 adults participated, and the study is already completed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Adalimumab
- What this could lead to
- If successful, this could help doctors understand how adalimumab works in the skin and guide better psoriasis treatments.
- What could go wrong
- This is a very small, early study (18 people) focused on gene patterns, not on proving the drug works. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chu Poitiers
Poitiers, 86021, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single cream tackle both skin and nail psoriasis?
- Psoriasis drug showdown: which pill works better?
- New hope for nail psoriasis: tildrakizumab shows promise in trial
- New drug bimekizumab shows promise for psoriasis in early trial
- New psoriasis drug shows promise in chinese trial
- Psoriasis drug showdown: which works better?